Mr. Louis Laflamme reports

OPSENS ANNOUNCES THE USE OF ITS PRODUCTS IN SEVERAL PATIENTS AT 21ST KAMAKURA LIVE DEMONSTRATION COURSE 2014 WITH DR SAITO

Opsens Inc.'s fractional flow reserve products were used in several patients during the 21st Kamakura Live Demonstration Course 2014 in Yokohama (Japan) by Dr. Shigeru Saito.

The OptoWire and OptoMonitor are Opsens's products for FFR measurements to optimize the diagnosis and guide the therapy in patients with coronary artery disease.

"The Kamakura Live Demonstration Course is an event to introduce to Japanese cardiologists new medical devices and practices intended to improve the treatment and the health of patients. Opsens's FFR products fit very well with this vision given the important benefits that they provide for efficiency and effectiveness in the treatment of coronary lesions. It was a great experience for me to demonstrate this new FFR system and I intend to continue using it," said Dr. Saito.

"Opsens's team is honoured to have their products used by Dr. Saito in the prestigious Kamakura Live Demonstration Course. The credibility of Dr. Saito and this event will be an asset to our marketing activities in Japan as well as around the world. Opsens is also pleased to announce that we have obtained a new regulatory approval in Japan for the latest generation of OptoWire. With this new generation FFR wire, we are now initiating our limited market launch with selected hospitals in Japan," said Louis Laflamme, president and chief executive officer of Opsens.

Opsens aims at becoming a key player in the guidewire FFR market with the OptoWire, a nitinol-based optical guidewire for FFR. The OptoWire provides intracoronary blood pressure measurements with unique, patented optical pressure guidewire technologies. It is immune to adverse effects related to blood contact, and allows easy and reliable connectivity that leads to reliable FFR measurements in extended conditions of usage. The OptoWire is also designed to provide cardiologists with a guidewire delivering optimized performances to navigate coronary arteries and reach blockages with ease. Based on industry sources, the FFR market represented over $250-million (U.S.) in sales in 2013 and is expected to reach $1-billion (U.S.) in the medium term. Opsens is confident that it is well positioned to capitalize on this significant growth opportunity.

We seek Safe Harbor.